God’s gifts: destiny, poverty, and temporality in the mines of Sierra Leone

In Sierra Leone, many artisanal miners share the view that every human act and every event is the realisation of an inscrutable divine plan. Even though notions of fate and destiny are part of the vocabulary of Krio, the country’s lingua franca, miners prefer to use expressions that evoke God and stress His immanent presence and influence in their everyday lives. In order to understand the religious vocabulary of contingency and the cosmology underlying the ways in which miners interpret, reproduce, and imaginatively prepare the conditions to change their lives, this article focuses on the ritual practices connected to artisanal diamond mining. It considers these rituals as attempts to resolve the ever-present temporal and moral tensions between actual conditions of suffering and poverty, and the realisation of the well-being that miners associate with their desired futures

Long Beach Earthquake and Protection Against Future Earthquakes -- Summary of Report by Joint Technical Committee on Earthquake Protection, Dr. Robert A. Millikan, Chairman

To the Public of the Pacific Southwest: In response to official requests from many representative technical and civic organizations, the Joint Technical Committee on Earthquake Protection was organized after the earthquake of March 10, 1933 to consider ways and means of minimizing loss of life and property damage in the event of another earthquake of equal or greater intensity. We now present to you, in the form of this summarized report, our belief as to the seismic hazard in this region and our opinion as to the proper balance between the degree of protection to be afforded life and property and the cost of providing such protection. We sincerely hope that the lessons of the Long Beach earthquake will not be forgotten as were the lessons which should have been fixed indelibly in the minds of all by the earthquakes of the past. Joint Technical Committee on Earthquake Protection. Robert A. Millikan, Chairman. June 7-1933

Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.

Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have thus far been disappointing owing to a lack of robust stratification methods. Whole-genome sequencing (WGS) analysis of 129 cases demonstrated that this is a heterogeneous cancer dominated by copy number alterations with frequent large-scale rearrangements. Co-amplification of receptor tyrosine kinases (RTKs) and/or downstream mitogenic activation is almost ubiquitous; thus tailored combination RTK inhibitor (RTKi) therapy might be required, as we demonstrate in vitro. However, mutational signatures showed three distinct molecular subtypes with potential therapeutic relevance, which we verified in an independent cohort (n = 87): (i) enrichment for BRCA signature with prevalent defects in the homologous recombination pathway; (ii) dominant T>G mutational pattern associated with a high mutational load and neoantigen burden; and (iii) C>A/T mutational pattern with evidence of an aging imprint. These subtypes could be ascertained using a clinically applicable sequencing strategy (low coverage) as a basis for therapy selection.Whole-genome sequencing of esophageal adenocarcinoma samples was performed as part of the International Cancer Genome Consortium (ICGC) through the oEsophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium and was funded by Cancer Research UK. We thank the ICGC members for their input on verification standards as part of the benchmarking exercise. We thank the Human Research Tissue Bank, which is supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, from Addenbrooke’s Hospital and UCL. Also the University Hospital of Southampton Trust and the Southampton, Birmingham, Edinburgh and UCL Experimental Cancer Medicine Centres and the QEHB charities. This study was partly funded by a project grant from Cancer Research UK. R.C.F. is funded by an NIHR Professorship and receives core funding from the Medical Research Council and infrastructure support from the Biomedical Research Centre and the Experimental Cancer Medicine Centre. We acknowledge the support of The University of Cambridge, Cancer Research UK (C14303/A17197) and Hutchison Whampoa Limited. We would like to thank Dr. Peter Van Loo for providing the NGS version of ASCAT for copy number calling. We are grateful to all the patients who provided written consent for participation in this study and the staff at all participating centres. Some of the work was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centres funding scheme. The work at UCLH/UCL was also supported by the CRUK UCL Early Cancer Medicine Centre.This is the author accepted manuscript. The final version is available from Nature Publishing Group via http://dx.doi.org/10.1038/ng.365